Public case informationLast updated
Erasca Securities Fraud Class Action
Erasca · Erasca securities and ERAS-0015 preclinical data · Ongoing Litigation
About this case
A complaint alleges that Erasca and other defendants misled investors about preclinical data for ERAS-0015, including alleged improper comparisons to RevMed and risks involving patent and trade secret protections. The complaint has been filed, the class has not yet been certified, and the lead-plaintiff deadline was August 10, 2026.
Case overview
- Defendant company
- Erasca
- Product or service
- Erasca securities and ERAS-0015 preclinical data
- Case status
- Ongoing Litigation
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Important dates
- Erasca Lead Plaintiff Application
Participation information
Erasca Lead Plaintiff Application
Investors who suffered losses on Erasca securities may have sought appointment as lead plaintiff, subject to the court's requirements.
A lead-plaintiff motion was required by August 10, 2026.
- Type
- Lead Plaintiff
- Status
- Deadline passed
- Reported proof requirement
- Unclear
Sources
- Erasca Securities Fraud Class Action
Barchart.com ·